TYK2 and psoriasis vulgaris: Janus kinase (JAK) inhibitors are immunosuppressive agents increasingly used in dermatology; among these, the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib is approved for use in moderate-to-severe plaque psoriasis.